Endocrinology Research and Practice
Original Article

Intensive Lipid Reduction and Proinflammatory Markers in the MODEST Study - Original Article

1.

Bolu Izzet Baysal, Medical Faculty, Department of Internal Medicine, Bolu, Turkey

2.

Şişli Etfal Education and Research Hospital, 2. Internal Medicine, Division of Endocrinology and Diabetes, Istanbul, Turkey

3.

Goztepe Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey

Endocrinol Res Pract 2010; 14: 31-34
Read: 2071 Downloads: 625 Published: 01 June 2010

Abstract
Objective:
 Statin therapy is well known to reduce inflammatory markers such as tumor necrosis factor-a (TNF-a), interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP). However, whether this relationship is maintained in the setting of targeting very low levels of LDL (<70 mg dl) in patients with type 2 diabetes has not been clearly established.
Materials and Methods: We measured hsCRP, IL-6, and TNF-a in 43 subject enrolled into the multicenter, open-label, crossover prospective study evaluating the effects of lipid-lowering treatment on steroid synthesis in patients with type 2 diabetes (MODEST study). Subjects with diabetes and coronary artery disease were treated with 80 mg of atorvastatin for 12 weeks. The effect of treatment on pro-inflammatory markers was assessed after 12 weeks.
Results: High-dose atorvastatin treatment significantly reduced the plasma levels of IL-6 and hsCRP (p<0.05, p<0.001, respectively), but not of TNF-a (p=0.051).
Conclusion: Atorvastatin treatment targeting very low LDL-cholesterol level reduced the levels of several important inflammatory markers in patients with type 2 diabetes and coronary heart disease. 

 

Files
EISSN 2822-6135